StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Ocular Therapeutix gross margin

Gross margin is gross profit as a percentage of revenue.

Ocular Therapeutix's gross margin for the twelve months ending Jun 30, 2026 was 87.1%. For fiscal 2025 it was 87.3%, against 91.2% the year before. The highest annual figure on record is 91.2% in fiscal 2022.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202587.3%−3.8
FY2024Dec 31, 202491.2%+0.2
FY2023Dec 31, 202391.0%−0.2
FY2022Dec 31, 202291.2%+1.3
FY2021Dec 31, 202189.9%+1.8
FY2020Dec 31, 202088.0%+43.0
FY2019Dec 31, 201945.0%−31.6
FY2018Dec 31, 201876.6%+0.4
FY2017Dec 31, 201776.2%−0.3
FY2016Dec 31, 201676.5%−5.2
FY2015Dec 31, 201581.8%−6.4
FY2014Dec 31, 201488.2%+58.2
FY2012Dec 31, 201230.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202685.1%−0.5
Q1 FY2026Mar 31, 202687.7%−0.5
Q4 FY2025Dec 31, 202588.0%−4.8
Q3 FY2025Sep 30, 202587.8%−2.1
Q2 FY2025Jun 30, 202585.6%−5.3
Q1 FY2025Mar 31, 202588.2%−2.8
Q4 FY2024Dec 31, 202492.8%+2.2
Q3 FY2024Sep 30, 202489.9%−1.0
Q2 FY2024Jun 30, 202490.8%−0.6
Q1 FY2024Mar 31, 202491.0%+0.1
Q4 FY2023Dec 31, 202390.6%−2.2
Q3 FY2023Sep 30, 202390.9%−0.2
Q2 FY2023Jun 30, 202391.4%+0.8
Q1 FY2023Mar 31, 202390.9%+0.8
Q4 FY2022Dec 31, 202292.8%+1.8
Q3 FY2022Sep 30, 202291.0%+1.8
Q2 FY2022Jun 30, 202290.6%−0.1
Q1 FY2022Mar 31, 202290.1%+2.3
Q4 FY2021Dec 31, 202191.0%+0.3
Q3 FY2021Sep 30, 202189.2%−3.1
Q2 FY2021Jun 30, 202190.6%−0.8
Q1 FY2021Mar 31, 202187.9%+19.2
Q4 FY2020Dec 31, 202090.7%+27.9
Q3 FY2020Sep 30, 202092.3%+89.6
Q2 FY2020Jun 30, 202091.5%+76.4
Q1 FY2020Mar 31, 202068.6%−5.4
Q4 FY2019Dec 31, 201962.8%−14.0
Q3 FY2019Sep 30, 20192.8%−74.1
Q2 FY2019Jun 30, 201915.1%−61.3
Q1 FY2019Mar 31, 201974.0%−2.5
Q4 FY2018Dec 31, 201876.8%−0.0
Q3 FY2018Sep 30, 201876.9%+0.8
Q2 FY2018Jun 30, 201876.4%+0.1
Q1 FY2018Mar 31, 201876.5%+0.7
Q4 FY2017Dec 31, 201776.8%+1.6
Q3 FY2017Sep 30, 201776.1%−0.4
Q2 FY2017Jun 30, 201776.3%–
Q1 FY2017Mar 31, 201775.8%–
Q4 FY2016Dec 31, 201675.1%–
Q3 FY2016Sep 30, 201676.5%–

More Ocular Therapeutix figures

See a number that looks wrong?